You are here: Home > Prescription(RX) Drugs > M > Moviprep (Physicians Total Care, Inc.)|
polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid
1 INDICATIONS AND USAGE
MoviPrep® is indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older.
2 DOSAGE AND ADMINISTRATION
The MoviPrep dose for colon cleansing for adult patients is 2 liters (approximately 64 ounces) of MoviPrep solution (with 1 additional liter of clear fluids) taken orally prior to the colonoscopy in one of the following ways:
Preparation of the MoviPrep solution:
MoviPrep solution is prepared by emptying the contents of 1 pouch A and 1 pouch B into a suitable glass container (or the container provided) and adding to the container 1 liter of lukewarm water. Mix the solution to ensure that the ingredients are completely dissolved. If the patient prefers, the MoviPrep solution can be refrigerated prior to drinking. The reconstituted solution should be used within 24 hours.
After consumption of the first liter of MoviPrep solution, the above mixing procedure should be repeated with the second pouch A and pouch B to reconstitute the second liter of the MoviPrep solution.
3 DOSAGE FORMS AND STRENGTHS
MoviPrep is available in a carton that contains 4 separate pouches (2 of pouch A and 2 of pouch B). Each pouch A contains 100 grams of polyethylene glycol (PEG) 3350, NF, 7.5 grams of sodium sulfate, USP, 2.691 grams of sodium chloride, USP, and 1.015 grams of potassium chloride, USP, plus the following excipients: aspartame, NF (sweetener), acesulfame potassium, NF (sweetener), and lemon flavoring. Each pouch B contains 4.7 grams of ascorbic acid, USP and 5.9 grams of sodium ascorbate, USP.
MoviPrep is contraindicated in patients who have had a severe hypersensitivity reaction to any of its components.
5 WARNINGS AND PRECAUTIONS
MoviPrep should be used with caution in patients with severe ulcerative colitis, ileus, gastrointestinal obstruction or perforation, gastric retention, toxic colitis, or toxic megacolon
Patients with impaired gag reflex and patients prone to regurgitation or aspiration should be observed during the administration of MoviPrep. If a patient experiences severe bloating, abdominal distention, or abdominal pain, administration should be slowed or temporarily discontinued until the symptoms abate. If gastrointestinal obstruction or perforation is suspected, appropriate tests should be performed to rule out these conditions before administration of MoviPrep®.
Phenylketonurics: MoviPrep contains phenylalanine – a maximum of 2.33 mg of phenylalanine per treatment.
No additional ingredients (e.g., flavorings) should be added to the MoviPrep solution.
Since MoviPrep contains sodium ascorbate and ascorbic acid, MoviPrep should be used with caution in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency especially G-6-PD deficiency patients with an active infection, with a history of hemolysis, or taking concomitant medications known to precipitate hemolytic reactions.5.1 Seizures
There have been rare reports of generalized tonic-clonic seizures associated with use of polyethylene glycol colon preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia). The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities. Therefore, MoviPrep should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities [such as diuretics or angiotensin converting enzyme (ACE)-inhibitors] or in patients with known or suspected hyponatremia. Consider performing baseline and post-colonoscopy laboratory tests (sodium, potassium, calcium, creatinine, and BUN) in these patients.
6 ADVERSE REACTIONS6.1 Clinical Studies Experience
In the MoviPrep trials, abdominal distension, anal discomfort, thirst, nausea, and abdominal pain were some of the most common adverse reactions to MoviPrep administration. Since diarrhea was considered as a part of the efficacy of MoviPrep, diarrhea was not defined as an adverse reaction in the clinical studies. Tables 1 and 2 display the most common drug-related adverse reactions of MoviPrep and its comparator in the controlled MoviPrep trials.
† 4L PEG + E is 4 liter Polyethylene Glycol plus Electrolytes Solution
* Drug-related adverse reactions were adverse events that were possibly, probably, or definitely related to the study drug. In addition to the recording of spontaneous adverse events, patients were also specifically asked about the occurrence of the following symptoms: shivering, anal irritations, abdominal bloating or fullness, sleep loss, nausea, vomiting, weakness, hunger sensation, abdominal cramps or pain, thirst sensation, and dizziness.
† OSPS is Oral Sodium Phosphate Solution
Isolated cases of urticaria, rhinorrhea, dermatitis, and anaphylactic reaction have been reported with PEG-based products and may represent allergic reactions.
Published literature contains isolated reports of serious adverse events following the administration of PEG-based products in patients over 60 years of age. These adverse events included upper gastrointestinal bleeding from a Mallory-Weiss tear, esophageal perforation, asystole, and acute pulmonary edema after aspirating the PEG-based preparation.6.2 Postmarketing Experience
In addition to adverse events reported from clinical trials, the following adverse events have been identified during post-approval use of MoviPrep. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to either their seriousness, frequency of reporting or causal connection to MoviPrep, or a combination of these factors.
General: Hypersensitivity reactions including anaphylaxis, rash, urticaria, lip and facial swelling, dyspnea, chest tightness and throat tightness.
7 DRUG INTERACTIONS
Oral medication administered within 1 hour of the start of administration of MoviPrep may be flushed from the gastrointestinal tract and the medication may not be absorbed.
8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy: Teratogenic Effects
Pregnancy Category C. Animal reproduction studies have not been performed with MoviPrep. It is also not known if MoviPrep can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. MoviPrep should be given to a pregnant woman only if clearly needed.8.3 Nursing Mothers
Because many drugs are excreted in human milk, caution should be exercised when MoviPrep is administered to a nursing woman.8.4 Pediatric Use
The safety and effectiveness of MoviPrep in pediatric patients
has not been established.
Of the 413 patients in clinical studies receiving MoviPrep, 91 (22%) patients were aged 65 or older, while 25 (6%) patients were over 75 years of age. No overall differences in safety or effectiveness were observed between geriatric patients and younger patients, and other reported clinical experience has not identified differences in responses between geriatric patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
There have been no reported cases of overdose with MoviPrep. Purposeful or gross accidental ingestion of more than the recommended dose of MoviPrep might be expected to lead to severe electrolyte disturbances, including hyponatremia and/or hypokalemia, as well as dehydration and hypovolemia, with signs and symptoms of these disturbances. The patient who has taken an overdose should be monitored carefully, and treated symptomatically for complications until stable.
MoviPrep® consists of 4 separate pouches (2 of pouch A and 2 of pouch B)
containing white to yellow powder for reconstitution. Each pouch A contains 100
grams of polyethylene glycol (PEG) 3350, NF, 7.5 grams of sodium sulfate, USP,
2.691 grams of sodium chloride, USP, and 1.015 grams of potassium chloride, USP,
plus the following excipients: aspartame, NF (sweetener), acesulfame potassium,
NF (sweetener), and lemon flavoring. Each pouch B contains 4.7 grams of ascorbic
acid, USP and 5.9 grams of sodium ascorbate, USP. When 1 pouch A and 1 pouch B
are dissolved together in water to a volume of 1 liter, MoviPrep (PEG-3350,
sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and
ascorbic acid) is an oral solution having a lemon taste.
12 CLINICAL PHARMACOLOGY
MoviPrep produces a watery stool leading to cleansing of the colon. The osmotic activity of polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid, when taken with 1 liter of additional clear fluid, usually results in no net absorption or excretion of ions or water.
The pharmacokinetics of MoviPrep have not been studied in patients with renal or hepatic insufficiency.
13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals to evaluate the carcinogenic potential have not been performed with MoviPrep®. Studies to evaluate potential for impairment of fertility or mutagenic potential have not been performed with MoviPrep®.
14 CLINICAL STUDIES
The colon cleansing efficacy and safety of MoviPrep was evaluated in two randomized, actively-controlled, multi-center, investigator-blinded, phase 3 trials in patients scheduled to have an elective colonoscopy.
In the first study, patients were randomized to one of the following two colon preparation treatments: 1) 2 liters of MoviPrep with 1 additional liter of clear fluid split into two doses (during the evening before and the morning of the colonoscopy) and 2) 4 liters of polyethylene glycol plus electrolytes solution (4L PEG + E) split into two doses (during the evening before and the morning of the colonoscopy). Patients were allowed to have a morning breakfast, a light lunch, clear soup and/or plain yogurt for dinner. Dinner had to be completed at least one hour prior to initiation of the colon preparation administration.
The primary efficacy endpoint was the proportion of patients with effective
colon cleansing as judged by blinded gastroenterologists on the basis of
videotapes recorded during the colonoscopy.
The efficacy analysis included 308 adult patients who had an elective colonoscopy. Patients ranged in age from 18 to 88 years old (mean age about 59 years old) with 52% female and 48% male patients. Table 3 displays the results.
* A: colon empty and clean or presence of clear liquid, but easily removed by suction
† B: brown liquid or semisolid remaining amounts of stool, fully removable by suction or displaceable, thus allowing a complete visualization of the gut mucosa
‡ C: semisolid amounts of stool, only partially removable with a risk of incomplete visualization of the gut mucosa
§ D: semisolid or solid amounts of stool; consequently colonoscopy incomplete or needed to be terminated. 4 L PEG+E's responder rate was not significantly higher than MoviPrep's responder rate.
¶ 4L PEG + E is 4 Liter Polyethylene Glycol plus Electrolytes Solution
In the second study, patients were randomized to one of the following two
colon preparation treatments: 1) 2 liters of MoviPrep with 1 additional liter
of clear fluid in the evening prior to the colonoscopy and 2) 90 mL of oral
sodium phosphate solution (90 mL OSPS) with at least 2 liters of additional
clear fluid during the day and evening prior to the colonoscopy. Patients
randomized to MoviPrep therapy were allowed to have a morning breakfast; a light
lunch; and clear soup and/or plain yogurt for dinner. Dinner had to be
completed at least one hour prior to initiation of the colon preparation
* A: empty and clean or clear liquid (transparent, yellow, or green)
† B: brown liquid or semisolid remaining small amounts of stool, fully removable by suction or displaceable allowing a complete visualization of the underlying mucosa
‡ C: semi solid only partially removable/displaceable stools; risk of incomplete examination of the underlying mucosa
§ D: heavy and hard stool making the segment examination uninterpretable and, consequently, the colonoscopy needed to be terminated
OSPS is Oral Sodium Phosphate Solution
MoviPrep's responder rate was not significantly higher than OSPS's responder rate.
16 HOW SUPPLIED/STORAGE AND HANDLING
MoviPrep® is supplied in powdered form. MoviPrep is administered as an oral solution after reconstitution.
NDC 54868-5890-0, MoviPrep, single use carton.
Each carton contains a disposable container for reconstitution of MoviPrep® and an inner carton containing 4 pouches (2 of pouch A and 2 of pouch B).
17 PATIENT COUNSELING INFORMATION
Important Precautions Regarding MOVIPREP
MoviPrep produces a watery stool which cleanses the colon before colonoscopy. It is recommended that patients receiving MoviPrep be advised to adequately hydrate before, during, and after the use of MoviPrep. Patients may have clear soup and/or plain yogurt for dinner, finishing the evening meal at least one hour prior to the start of MoviPrep treatment. No solid food should be taken from the start of MoviPrep treatment until after the colonoscopy.
What Patients Should Know About Adverse Reactions
The first bowel movement may occur approximately 1 hour after the start of MoviPrep administration. Abdominal bloating and distention may occur before the first bowel movement. If severe abdominal discomfort or distention occurs, stop drinking temporarily or drink each portion at longer intervals until these symptoms disappear.
© 2006 Salix Pharmaceuticals, Inc.
Product protected by U.S. Patent No. 7169381 and other pending applications
PRINCIPAL DISPLAY PANEL
This carton contains
Revised: 11/2009 Physicians Total Care, Inc.
Reproduced with permission of U.S. National Library of Medicine
Copyright © 2019
|Over-the-counter (OTC) Drugs|